Hyphens Pharma, a subsidiary of Hyphens Pharma International Limited, Singapore’s leading specialty pharmaceutical and consumer healthcare group, has announced the launch of Winlevi (clascoterone) cream 1% in Singapore and Malaysia, marking its first entry into Southeast Asia.
This launch is made possible through an exclusive license and supply agreement with Cassiopea S.p.A., a subsidiary of Cosmo Pharmaceuticals N.V. The agreement covers Winlevi and its future product extensions and improvements across 10 Southeast Asian countries (Singapore, Malaysia, Indonesia, Philippines, Vietnam, Thailand, Brunei, Cambodia, Laos and Myanmar).
Winlevi is the first new class of molecule in acne treatment in over 40 years, acting through a novel mechanism of action that targets the androgen-sebum pathway directly within the skin. Its active ingredient, clascoterone, is the first commercially available topical androgen receptor inhibitor for acne, reducing sebum production and inflammation without causing systemic anti-androgen side effects. This makes it a safe choice for both male and female patients with acne.
With the addition of Winlevi, Hyphens Pharma strategically advances its dermatology portfolio, one of its core therapeutic focus areas. The company’s proprietary dermatology portfolio currently includes treatments for acne, atopic dermatitis, hyperpigmentation, and hair loss, distributed through dermatologists, paediatricians, general practitioners and major retail pharmacies across Southeast Asia.
Winlevi officially launched in Singapore and Malaysia in July 2025 and will be available via prescription through clinics and hospitals. Registration in other Southeast Asian markets is currently underway, with a progressive rollout planned across the region in due course.
